Lupin Ltd.
NSE: LUPIN · Healthcare
Sector
Healthcare
Size band
Large cap
Market cap
1,04,996cr
P/E
19.1
ROE
17.8%
Dividend yield
0.5%
No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.
Measured against
Peer set
Pharmaceuticals & Drugs · largest 12 of 82 measured at Q1 FY27 · financials via Screener| Company | Operating margin | Revenue growth |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 29.0% | 10.5% |
| Divi's Laboratories Ltd. | 41.0% | 27.8% |
| Torrent Pharmaceuticals Ltd. | 34.0% | 54.8% |
| Lupin Ltd. | 30.0% | 32.1% |
| Dr. Reddy's Laboratories Ltd. | 11.0% | −5.5% |
| Cipla Ltd. | 17.0% | 2.3% |
| Zydus Lifesciences Ltd. | 24.0% | 22.0% |
| Mankind Pharma Ltd. | 26.0% | 12.9% |
| Aurobindo Pharma Ltd. | 21.0% | 16.3% |
| Torrent Power Ltd. | 19.0% | 2.8% |
| Alkem Laboratories Ltd. | 20.0% | 10.9% |
| Glenmark Pharmaceuticals Ltd. | 20.0% | 23.1% |
No guidance on record.
This section quotes what management told the market on the quarterly earnings call. We have not transcribed one for Lupin Ltd..
On air
20 calls · outcomes not trackedRecorded as stated on air, with the analyst's SEBI registration status where it was given. Anchor calls carry no registration and are marked. Bharatstox does not make, endorse or repeat these calls, and none of them is our view.
| Channel & show | Aired | Stated target | Stated stop | Outcome |
|---|---|---|---|---|
| CNBC AwaazCNBC Awaax · no registration attached | 22 Sep | +31.2% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 22 Sep | +30.4% | — | still open |
| Zee BusinessZee Business · no registration attached | 21 Sep | +8.3% | -5.8% | still open |
| Zee BusinessZee Business · no registration attached | 21 Sep | +9.1% | -5.2% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 17 Sep | +28.2% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 17 Sep | +28.2% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 17 Sep | +28.4% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 17 Sep | +28.6% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 17 Sep | +28.4% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 17 Sep | +29.0% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 17 Sep | +29.2% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 17 Sep | +29.2% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 17 Sep | +30.0% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 17 Sep | +30.0% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 17 Sep | +29.9% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 17 Sep | +29.7% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 17 Sep | +29.8% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 17 Sep | +30.2% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 17 Sep | +30.5% | — | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 17 Sep | +30.6% | — | still open |
Shareholding
change across 4 filings| Category | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Change |
|---|---|---|---|---|---|
| Promoters | 46.9 | 46.9 | 46.9 | 46.9 | 0.0 |
| Foreign institutions | 22.4 | 21.7 | 21.5 | 20.5 | +1.9 |
| Domestic institutions | 24.7 | 25.3 | 25.6 | 26.6 | −1.9 |
| Retail & others | 6.1 | 6.1 | 6.0 | 6.1 | 0.0 |
As filed with the exchange for the periods ending Sep 25 to Jun 26.
Filings
latest 25 of 556- General Updates15 Oct 2026
- Certificate under SEBI (Depositories and Participants) Regulations, 20189 Oct 2026
- Press Release8 Oct 2026
- Press Release6 Oct 2026
- General Updates1 Oct 2026
- Trading Window28 Sept 2026
- Press Release28 Sept 2026
- ESOP/ESOS/ESPS21 Sept 2026
- Intimation of allotment of 24,111 equity shares under ESOP.21 Sept 2026
- Intimation about participating in the Analyst/Institutional Investors Meet.8 Sept 2026
- Analysts/Institutional Investor Meet/Con. Call Updates8 Sept 2026
- Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP.4 Sept 2026
- Press Release4 Sept 2026
- General Updates28 Aug 2026
- ESG Rating by Crisil ESG Ratings & Analytics Ltd.28 Aug 2026
- Intimation of allotment of 30967 equity shares under ESOP.25 Aug 2026
- ESOP/ESOS/ESPS25 Aug 2026
- ESG Rating by ESG Risk Assessment and Insights Limited.24 Aug 2026
- General Updates24 Aug 2026
- VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.20 Aug 2026
- Arrangements for strategic, technical, manufacturing, or marketing tie up20 Aug 2026
- Intimation of Demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company.18 Aug 2026
- Demise18 Aug 2026
- Press Release17 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates12 Aug 2026
The 25 most recent of 556 filings we hold for LUPIN, back to January 2024. Every filing, by day.
Disclaimer
Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Peer comparisons use quarterly financials sourced from Screener, with every company measured at the same fiscal quarter; the peer set is companies sharing the same industry classification, and comparisons are descriptive, not a ranking or a view. Broadcast calls are reproduced as stated on air, attributed, with the analyst's SEBI registration status where given; they are not our calls and not our view. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.